These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 38612640)

  • 1. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
    Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
    Soresi M; Giannitrapani L
    World J Gastroenterol; 2024 Aug; 30(30):3541-3547. PubMed ID: 39193573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Abdelmalek MF; Harrison SA; Sanyal AJ
    Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
    Newsome PN; Ambery P
    J Hepatol; 2023 Dec; 79(6):1557-1565. PubMed ID: 37562748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
    Jakubowska A; Roux CWL; Viljoen A
    Endocrinol Metab (Seoul); 2024 Feb; 39(1):12-22. PubMed ID: 38356208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
    Mentis N; Vardarli I; Köthe LD; Holst JJ; Deacon CF; Theodorakis M; Meier JJ; Nauck MA
    Diabetes; 2011 Apr; 60(4):1270-6. PubMed ID: 21330636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.
    Xie C; Alkhouri N; Elfeki MA
    World J Hepatol; 2024 May; 16(5):731-750. PubMed ID: 38818288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists].
    Scheen A
    Rev Med Liege; 2024 Sep; 79(9):605-612. PubMed ID: 39262368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
    Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
    Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK
    Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.